A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling \textit{in vitro} and inhibits insulin-like growth factor-I receptor–dependent tumor growth \textit{in vivo}

Qun-sheng Ji, Mark J. Mulvihill, Maryln Rosenfeld-Franklin, Andrew Cooke, Lixin Feng, Gilda Mak, Matthew O’Connor, Yan Yao, Caroline Pirritt, Elizabeth Buck, Alexandra Eyzaguirre, Lee D. Arnold, Neil W. Gibson, and Jonathan A. Pachter

(OSI) Oncology, OSI Pharmaceuticals, Inc., New York, New York

Abstract

Insulin-like growth factor-I receptor (IGF-IR) and its ligands, IGF-I and IGF-II, are up-regulated in a variety of human cancers. In tumors, such as colorectal, non–small cell lung, ovarian, and pediatric cancers, which may drive their own growth and survival through autocrine IGF-II expression, the role of IGF-IR is especially critical. Here, we present a novel small-molecule IGF-IR kinase inhibitor, \textit{cis}-3-[(4-methyl-piperazin-1-yl)-cyclobutyl]-1-[(2-phenylquinolin-7-yl)-imidazo[1,5-a]pyrazin-8-yl]amine (PQIP), which displayed a cellular IC\textsubscript{50} of 19 nmol/L for inhibition of ligand-dependent autophosphorylation of human IGF-IR with 14-fold cellular selectivity relative to the human insulin receptor. PQIP showed minimal activity against a panel of 32 other protein kinases. It also abolished the ligand-induced activation of downstream phosphorylated AKT and phosphorylated extracellular signal-regulated kinase 1/2 in both IGF-II transfectant cells and a GEO human colorectal cancer cell line. Analysis of GEO cells revealed a significant level of both phosphorylated IGF-IR and IGF-II expression. Furthermore, inactivation of IGF-II in conditioned GEO culture medium by a neutralizing antibody diminished IGF-IR activation, indicating the presence of a functional IGF-II/IGF-IR autocrine loop in GEO cells. Once daily oral dosing of PQIP induced robust antitumor efficacy in GEO xenografts. The antitumor efficacy correlated with the degree and duration of inhibition of tumor IGF-IR phosphorylation \textit{in vivo} by this compound. Moreover, when mice were treated for 3 days with a dose of PQIP that maximally inhibited tumor growth, only minor changes in blood glucose were observed. Thus, PQIP represents a potent and selective IGF-IR kinase inhibitor that is especially efficacious in an IGF-II–driven human tumor model. [Mol Cancer Ther 2007;6(8):2158–67]

Introduction

The insulin-like growth factor-I receptor (IGF-IR) is a tetrameric transmembrane receptor tyrosine kinase that is widely expressed in normal human tissues and is involved in embryonic development and postnatal growth. The receptor is composed of two α and two β subunits linked by disulfide bonds. The extracellular α subunit is responsible for ligand binding, whereas the β subunit consists of a transmembrane domain and a cytoplasmic tyrosine kinase domain. The receptor is activated by its cognate ligands, insulin-like growth factor-I (IGF-I) and IGF-II, and to a lesser extent by insulin (500- to 1,000-fold less potent; ref. 1). Ligand binding activates the intrinsic tyrosine kinase activity of IGF-IR, resulting in trans-α subunit autophosphorylation and the stimulation of signaling cascades that include the IRS-1/phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin and growth factor receptor binding protein 2/Sos/Ras/mitogen-activated protein kinase pathways. Activation of IGF-IR has been reported to stimulate proliferation, survival, transformation, metastasis, and angiogenesis (1–6). Inhibition of IGF-IR by various approaches, including antisense (7, 8), anti–IGF-IR antibodies (9–12), dominant-negative IGF-IR (13–15), and small-molecule inhibitors (16–19), has been shown to reduce tumor growth in human tumor xenograft models. Increased expression of IGF-I and IGF-II and their corresponding receptor, IGF-IR, has been shown in a broad range of solid tumors and hematologic neoplasias relative to corresponding normal tissue (3–6, 20–23). IGF-I is mainly produced in the liver, whereas IGF-II is synthesized locally in an autocrine or paracrine manner. Because IGF-IR is a monomeric binding protein without tyrosine kinase activity, IGF-IR seems to function as the predominant signaling receptor for both IGF-I and IGF-II. The link between cancer and IGF signaling is further supported by epidemiologic studies showing an increased relative risk for the development of colon, prostate, breast, lung, and bladder cancers in individuals with circulating IGF-I levels in the upper tertile of the reference range (24–28). Moreover, tumor IGF-I expression correlates with poor prognosis in renal cell carcinoma (29). Furthermore, IGF-IR

Received 1/31/07; revised 5/2/07; accepted 6/29/07.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Qun-sheng Ji, Department of Cancer Biology, 1 Bioscience Park Drive, Farmingdale, NY 11735. Phone: 631-962-0670; Fax: 631-845-5671. E-mail: qji@osip.com

Copyright © 2007 American Association for Cancer Research.
doi:10.1158/1535-7163.MCT-07-0070

Mol Cancer Ther 2007;6(8). August 2007
signaling may be a mechanism of resistance to various antitumor therapies, including epidermal growth factor receptor inhibitors (30). It is notable that although no specific mutations in IGF receptors or ligands have been identified in cancers, there is clear evidence of epigenetic alterations; that is, loss of imprinting or other regulatory failures that lead to increased IGF-II expression in a variety of human tumors, including colorectal (31, 32), ovarian (33, 34), lung (35), liver (36), and pediatric cancers (23). Indeed, IGF-II is the gene most overexpressed in colon cancers compared with normal colon mucosa (31) and loss of imprinting of IGF-II represents a risk factor for colorectal cancer (37). These data clearly indicate that an active IGF-II autocrine loop can play an important role in colon cancer progression.

Here, we report a potent and selective IGF-IR tyrosine kinase inhibitor, cis-3-[3-(4-methyl-piperazin-1-yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-\text{a}][1,3]pyrazin-8-ylamine (PQIP), that potently inhibits human IGF-IR with 14-fold selectivity over human insulin receptor (IR) in intact cells. Moreover, PQIP inhibits cell proliferation and induces apoptosis through a mechanism that includes inhibition of AKT activation. The promising pharmacokinetic and pharmacodynamic properties of the compound together with robust antitumor activity observed in an IGF-II autocrine xenograft model suggest potential clinical utilities for IGF-IR kinase inhibitors, such as PQIP, in colon cancer and other human malignancies.

Materials and Methods

Synthesis of PQIP

PQIP is a 1,3-disubstituted-8-amino-imidazopyrazine derivative (Fig. 1A) synthesized by the methods described in patent application WO 2005/097800 A1 (38). Compound identity and purity (>99%) were verified by 1H and 13C nuclear magnetic resonance, mass spectrometry, and high-performance liquid chromatography using Bruker Avance 400, WatersMicromass ZQ, and Waters LC Module I Plus instruments, respectively, as well as by elemental analysis. PQIP was dissolved in DMSO at 10 mmol/L for use in biochemical or cellular in vitro assays. For in vivo studies, PQIP was dissolved in 25 mmol/L tartaric acid at an appropriate concentration to deliver the desired dose of 10 mL/kg by oral gavage.

Cell Lines

3T3/huIGF1R fibrosarcoma cells, derived from NIH 3T3 cells stably overexpressing full-length human IGF-IR, were obtained from Dr. J. Beebe (Pfizer, Inc., Ann Arbor, MI). GEO human colorectal cancer cells were kindly provided by Dr. M. Brattain (Roswell Park Cancer Institute, Buffalo, NY) and were maintained in McCoy’s 5A medium supplemented with 10% FCS and 1% L-glutamine or in serum-free conditioned culture system. Cell lines NCI-H292, HepG2, Hepa-1, SW620, Colo205, SW480, HT29, HCT116, HCT8, MCF-7, DU4475, BxPC3, MiaPaca2, HPAC, Panc1, and A1165 were grown in medium as prescribed by the American Type Culture Collection containing 10% FCS.

Antibodies

The following antibodies were used for immunoprecipitation or as the capture antibody in ELISA assays: human IGF-IR (Ab-1, Calbiochem), human IR (Lab Vision Corp.), and mouse IR (Santa Cruz Biotechnology) for capture; human IGF-IRβ (Santa Cruz Biotechnology), antiphosphotyrosine (Exalpha Biologicals), antiphosphotyrosine-horseradish peroxidase (HRP) conjugate (mouse anti-phosphotyrosine-HP, Invitrogen-Zymed), phosphorylated AKT\textsuperscript{1,\text{Thr}183,\text{Ser}197} (Cell Signaling Technology), phosphorylated AKT\textsuperscript{473} (Cell Signaling Technology), total AKT (Cell Signaling Technology), phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) (ERK1/2; Cell Signaling Technology), p-p70S6K (Cell Signaling Technology), and cleaved poly(ADP)ribose polymerase (Cell Signaling Technology).

Animals

Female CD-1 and athymic nude \textit{nu/nu} CD-1 mice (6–8 weeks, 25–29 g) were obtained from Charles River Laboratories. Animals were allowed to acclimate for a minimum of 1 week before initiation of a study. Throughout the studies, animals were allowed sterile rodent chow and water \textit{ad libitum}, and immunocompromised animals were maintained under specific pathogen-free conditions. All animal studies were conducted at OSI facilities with the approval of the Institutional Animal Care and Use Committee in an American Association for Accreditation of Laboratory Animal Care–accredited vivarium and in accordance with the Institute of Laboratory Animal Research (Guide for the Care and Use of Laboratory Animals, NIH, Bethesda, MD).

Protein Kinase Biochemical Assays

Protein kinase assays were either done in-house by ELISA-based assay methods (IGF-IR, IR, Kit, epidermal growth factor receptor, and kinase insert domain receptor) or at Upstate, Inc., by a radiometric method (KinaseProfiler service). In-house ELISA assays used poly(Glu:Tyr) (Sigma) as the substrate bound to the surface of 96-well assay plates, and phosphorylation was detected using an antiphosphotyrosine antibody conjugated to HRP. The bound antibody was quantified using 2,2’azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) as the peroxidase substrate by measuring absorbance at 405/490 nm. All assays used purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-IR, Kit, or epidermal growth factor receptor were expressed as an NH\textsubscript{2}-terminal glutathione S-transferase fusion protein in insect cells, and were purified in-house (39). The human IR protein was purchased from Calbiochem.

Protein Kinase Inhibition in Intact Cells

Quantitative 96-well ELISA assays were developed to study the cellular effects of PQIP. Cells were plated into 96-well plates and cultured overnight before serum starvation (0.5% FCS) at 37°C for 2 h (3T3/huIGF1R) or overnight (HepG2 and Hepa-1). They were then treated...
with various concentrations of compound for 2 h before lysis (the final DMSO concentration in the assay was 0.4%), and IGF-I (100 ng/mL, R&D Systems) or insulin (10 ng/mL, Roche) was added for the final 15 min of the compound treatment period. Lysates were prepared in TGH buffer [1% Triton X-100, 10% glycerol, 50 mmol/L HEPEs (pH 7.4); ref. 40] supplemented with 150 mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EDTA, and fresh protease and phosphatase inhibitors (10 μg/mL leupeptin, 25 μg/mL aprotonin, and 200 μmol/L Na3VO4). ELISA assays of the target protein phosphorylation were done by transferring lysates into a second 96-well plate that was precoated with the appropriate capture antibody. The target proteins were then probed with an antiphosphotyrosine antibody HRP conjugate using a chemiluminescent HRP substrate (Pierce) for detection by luminometry. In experiments to evaluate the effect of plasma protein binding on PQIP potency, whole plasma from mouse, dog, or human was incorporated into the quantitative 96-well assays at a concentration of 90%. In these experiments, plasma was added to the cell culture medium before compound addition.

For immunoblotting analysis, lysates were cleared of insoluble material by centrifugation at 15,000 × g for 5 min at 4°C and the resultant supernatant was subjected to immunoprecipitation with the appropriate antibody coupled to Protein G-Sepharose beads (Sigma), followed by SDS-PAGE and immunoblotting with antiphosphotyrosine antibody-HRP conjugate and chemiluminescent detection. Alternatively, for highly abundant protein targets [IGF-IR, ERK1/2, Akt, p70S6K and cleaved-poly(ADP)ribose polymerase], lysates were analyzed directly by SDS-PAGE and immunoblotting.

**Cell Proliferation and Anchorage-Independent Growth**

For assays of cell proliferation, cells were seeded into 96-well plates and incubated for 3 days in the presence of PQIP at various concentrations. Inhibition of cell growth was determined by luminescent quantitation of intracellular ATP content using CellTiterGlo (Promega). For assay of anchorage-independent growth, 2 × 106 cells were plated in semisolid medium containing 0.35% agar (MED, 10% FCS, and compound at indicated concentrations. The plates were incubated at 37°C for 14 to 18 days. Colonies were scored with the alpha imager (Alpha Innotech) after 2 h staining with methylthiazolylidiphenyltetrazolium bromide (1 mg/mL).

**IGF-II Autocrine IGF-IR Phosphorylation in GEO Cells**

For analysis of an IGF autocrine loop in intact cells, cells were seeded into 10-mm dishes in the appropriate cell culture medium supplemented with 10% FCS. After 24 h, the cell culture medium was replaced with fresh medium without FCS for the indicated time periods. Cells were then stimulated with or without IGF-I (100 ng/mL, R&D Systems) for 15 min before being lysed, followed by immunoanalysis of phosphorylated IGF-IR content. To prepare conditioned medium, media were collected from 72 h incubation of GEO or NCI-H292 cultures in the appropriate medium containing 0.1% bovine serum albumin without FCS, and then centrifuged at 15,000 × g for 10 min at 4°C to remove all contaminating cells. The conditioned medium was then preincubated with either normal IgG or an IGF-II neutralizing antibody (AF-292-NA, R&D Systems) for 2 h at 37°C before stimulating serum-starved NCI-H292 cells for 15 min at 37°C. The cells were lysed and proteins were analyzed by immunoprecipitation and immunoblotting for both total and phosphorylated (p) target protein content. IC50 values were calculated based on the phosphorylated protein content quantified using densitometry.

**Figure 1.** Inhibition of ligand-stimulated phosphorylated IGF-IR, phosphorylated AKT, phosphorylated ERK1/2, and phosphorylated p70S6K by PQIP in 3T3/huIGF1R cells. A, chemical structure of PQIP. B, serum-starved 3T3/huIGF1R cells were incubated with PQIP at indicated concentrations for 2 h at 37°C, followed by stimulation with IGF-I and ligand for 15 min. Cell lysates were then analyzed by immunoprecipitation and immunoblotting for both total and phosphorylated (p) target protein content. IC50 values were calculated based on the phosphorylated protein content quantified using densitometry.
deoxynucleotide triphosphates). For amplification of IGF-I, 35 cycles of PCR reactions were programmed as follows: 94°C, 1 min/55°C, 1 min/72°C, 2 min, followed by a final 5-min extension at 72°C. For PCR of IGF-II, the annealing temperature was raised to 60°C. The primers for amplification of IGF-I were as follows: IGF-I sense, 5'-CTTCTCAA-CATCTCCCATCTC-3'; IGF-I antisense, 5'-CCTCCTTAGA-TCACAGCTCC-3'. The primers for amplification of IGF-II sequences were IGF-II sense, 5'-AGTGCAGTGGTGCT-TCTCA-3' and IGF-II antisense 5'-GTGGGCCTGGGTCT-TGGGTGGGTAG-3'.

**Pharmacokinetic Analysis of PQIP**

For pharmacokinetic analysis, the compound was formulated in saline adjusted to pH 2 with 0.01 mol/L hydrochloric acid for i.v. injection, and in 25 mmol/L tartaric acid for oral administration. Female CD-1 mice (6–10 weeks old) received either a single i.v. dose (10 mg/kg) or a single oral dose (5–200 mg/kg) of compound. For i.v. dosing, compound was delivered via tail vein injection at a dosing volume of 4 mL/kg. For oral dosing, compound was delivered via oral gavage in a dosing volume of 10 mL/kg. Subsequently, three animals were sacrificed at each designated time point and blood samples were collected in EDTA. After centrifugation at 1,500 g for 10 min, plasma samples were prepared by protein precipitation with methanol and analyzed by high-performance liquid chromatography-tandem mass spectrometry (PE Sciex API 3000 LC/tandem mass spectrometry System, Applied Biosystems). Pharmacokinetic variables for the plasma time-concentration profile, including Cmax area under the curve (AUC), elimination half-life (t1/2), volume of distribution at steady-state (Vss), clearance, mean residence time, and oral bioavailability, were calculated by noncompartmental analysis.

**Pharmacodynamic Analysis of Phosphorylated IGF-IR Inhibition In vivo**

To assess the ability of compounds to inhibit phosphorylated IGF-IR in tumors, female nu/nu CD-1 mice were implanted s.c. with either 3T3/huIGF1R or GEO cells. When tumors reached ~300 mm3, mice were orally dosed with vehicle or compound, at the indicated doses. Both tumors and plasma were collected at appropriate time points for analysis of IGF-IR phosphorylation (tumor samples) and PQIP concentrations (plasma samples). The phosphorylation status of IGF-IR was determined by the following: Tumors were homogenized in 1 mL TGH buffer per 200 mg tumor using a tissue homogenizer (Tissue-Tearor, BioSpec) on ice at 5,000 to 30,000 rpm until the tumor tissue was completely broken down. Following precooling by centrifugation at 14,000 rpm for 5 min at 4°C, ~1 mg of tumor lysate was incubated with an antiphosphotyrosine antibody overnight at 4°C with rotation, and 30 μL Protein-A Sepharose (Sigma) was then added and incubation continued for an additional 2 h to overnight at 4°C. The immunoprecipitates were separated on SDS-PAGE and immunoblotted with a total IGF-IR antibody (Santa Cruz) followed by detection using an HRP-conjugated goat anti-rabbit IgG antibody (Cell Signaling) with enhanced chemiluminescence. For determination of total IGF-IR, a direct immunoblotting was used as described above using the sc-713 antibody. The phosphorylated IGF-IR and total IGF-IR bands were quantified using a Bio-Rad GS-800 Densitometer. The phosphorylated IGF-IR signal was normalized to total IGF-IR.

**In vivo Antitumor Efficacy**

Cells were harvested from cell culture flasks during exponential cell growth, washed twice with sterile PBS, counted, and resuspended in PBS to a suitable concentration before s.c. implantation on the right flank of nu/nu CD-1 mice. Tumors were established to 200 ± 50 mm3 in size before randomization into treatment groups of eight mice each for efficacy studies. PQIP or vehicle was administered orally as indicated. Body weights were determined twice weekly along with tumor volume [V = length × (width)2] / 2] measurements using Vernier calipers during the study. Tumor growth inhibition (TGI) was determined at different time points by the following formula: % TGI = (1 – [(Tt / To) / (Ct / C0)] / 1 – (C0 / C1)) × 100, where Tt = median tumor volume of treated at time t, To = median tumor volume of treated at time 0, Ct = median tumor volume of control at time t, and C0 = median tumor volume of control at time 0. Mean TGI was calculated for the entire dosing period, with 50% TGI considered to be the minimal response required for efficacy. Growth delay was calculated as T – C, where T and C are the times in days for median tumor size in the treated (T) and control (C) groups to reach 400% of the initial tumor volume. Cures were excluded from this calculation.

**Glucose Tolerance Test**

CD-1 mice were dosed orally for 3 consecutive days with PQIP or vehicle. Mice were fasted for 8 h (water ad libitum) before final administration of treatments. Glucose (dextrose in water for injection, 20% solution) was administered at 2 g/kg by i.p. injection immediately after the third oral dose of compound (41). Blood samples were collected for glucose evaluation by tail vein stick at various time points after final compound dosing. Blood glucose levels were measured using a Glucose-201 instrument from HemoCue, Inc.

**Results and Discussion**

**In vitro Activity of PQIP in Biochemical Assays**

PQIP (Fig. 1A) was designed and subsequently optimized through structure-based design efforts that built upon cocystal structures of earlier benzyloxyphenyl-derivated imidazopyrazines with IGF-IR and IR (data not shown). PQIP potently inhibits the activity of recombinant kinase domains derived from the closely related receptor tyrosine kinases IGF-IR and IR when assayed using poly(Glu:Tyr) as the substrate at an ATP concentration of 100 μmol/L (Supplementary Table S1).1 Both a cocystal

1 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).
structure and kinetic observations of effects of ATP on potency indicate that PQIP binds competitively to the ATP-binding pocket (data not shown). PQIP has also been assayed for inhibitory activity against 32 additional purified protein kinases representing tyrosine and serine/threonine kinase families and <50% inhibitory activity for these kinases was observed at 10 μmol/L of PQIP (Supplementary Table S1). ATP at 100 μmol/L concentration was used in the kinase profiling for direct comparison with IGF-IR and IR kinase activities. Hence, the counterscreening data indicate that PQIP is a potent and selective IGF-IR kinase inhibitor versus the kinases that were profiled, and the only known activity of significance is the inhibition of the highly homologous insulin receptor.

In vitro Activity of PQIP in Intact Cells

PQIP was tested for inhibition of ligand-stimulated IGF-IR tyrosine kinase activity in intact cells. In 3T3/huIGF1R cells, an NIH-3T3 line stably overexpressing full-length human IGF-IR, PQIP fully inhibits IGF-I–stimulated receptor tyrosine autophosphorylation using immunoprecipitation and immunoblotting analysis of cell lysates (Fig. 1B). PQIP also inhibits IGF-I–stimulated AKT and ERK1/2 signaling pathways in 3T3/huIGF1R cells. In addition to phosphorylated IGF-IR, phosphorylated ERK, and phosphorylated AKT inhibition, similar dose-dependent reduction in the level of phosphorylated p70S6K was observed when the cells were exposed in vitro to PQIP (Fig. 1B). In cell-based functional assays, PQIP inhibited IGF-I– and IGF-II–induced proliferation of 3T3/huIGF1R cells, and showed reduced antiproliferative potency in the presence of 10% FCS, suggesting that other serum factors can drive proliferation of this cell line through receptors other than IGF-IR (Table 1).

To functionally assess the influence of plasma protein binding on the biological potency of the compound across various species, 90% whole plasma from mouse, dog, or human was included in the IGF-IR cellular autophosphorylation assay. Significantly different shifts in the cellular potency of PQIP were observed upon the inclusion of plasma from several species (Table 2). The greatest potency shift was observed in the presence of mouse plasma, which increased the IC₅₀ by ~45-fold, whereas lesser effects were observed with human and dog plasma (~6- to 7-fold IC₅₀ increases). These differential potency shifts of PQIP were consistent with direct measurements of the binding of PQIP to plasma proteins from these species conducted at Ricerca Biosciences (data not shown), suggesting that greater exposures will be necessary in mice than in dogs and humans to overcome the effects of plasma. Because 90% whole plasma was used in the assay to predict physiologically relevant plasma exposures, the differential protein binding effects may be used to estimate equivalent exposures in other species relative to the efficacy observed in mouse models when assessing the therapeutic window of PQIP.

IGF-IR/IR Selectivity of PQIP in Intact Cells

To assess the ability of PQIP to inhibit the human IR tyrosine kinase in intact cells, a cellular assay using a human hepatoma cell line (HepG2) was developed. The IC₅₀ of PQIP for human IR was 261 nmol/L in HepG2 cells (Table 2). HepG2 cells predominantly express IR (both A and B isoforms) and minimal IGF-IR, and insulin does not appreciably activate IGF-IR at the concentrations used in the assay (e.g., 10 ng/mL; data not shown; ref. 42). Hence, PQIP was found to be ~14-fold more potent toward human IGF-IR than human IR (Table 2). It was also found that mouse IR is more sensitive to PQIP than human IR

<table>
<thead>
<tr>
<th>Target</th>
<th>IGF-IR</th>
<th>Insulin receptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Human</td>
<td>Human</td>
</tr>
<tr>
<td>+ 90% plasma</td>
<td>None</td>
<td>Human</td>
</tr>
<tr>
<td>IC₅₀ (μmol/L)</td>
<td>0.019</td>
<td>0.111</td>
</tr>
<tr>
<td>Selectivity (IR/IGF-IR)</td>
<td>14-fold</td>
<td>4-fold</td>
</tr>
</tbody>
</table>

NOTE: IC₅₀ for inhibition of ligand-stimulated targets in intact cells was determined using a quantitative ELISA assay. For human IGF-IR, 3T3/huIGF1R cells were serum starved for 2 h and then treated with PQIP for 2 h in the absence or presence of 90% whole plasma from either human, dog, or mouse, followed by stimulation with IGF-1 ligand (100 ng/mL) for 15 min. For human IR (HepG2) or mouse IR (Hepa-1), the cells were starved overnight before 2-h treatment with PQIP, followed by 15-min stimulation with human insulin (10 ng/mL). Inhibition of the target enzymes was determined by monitoring effects of IGF-1 or insulin-stimulated receptor autophosphorylation. IC₅₀ values were determined from the sigmoidal dose-response plot of percentage inhibition versus log₁₀ compound concentration (Xfit 3.0, IDBS). Fold selectivity for human IGF-IR relative to human or mouse IR was calculated by dividing the IC₅₀ values for IR by the IC₅₀ values for human IGF-IR.
when assayed using a mouse hepatoma cell line Hepa-1 (Table 2), which expresses mouse IR but lacks IGF-IR (data not shown). The IGF-IR/IR selectivity of PQIP was further confirmed by determination of IGF-IR IC\textsubscript{50} values in additional cell lines expressing endogenous human IGF-IR (HT29 and A431) and determination of IR IC\textsubscript{50} values in primary human hepatocytes that express only IR. These cell lines showed comparable IGF-IR and IR potencies to those determined with 3T3/huIGF1R and HepG2 cells (data not shown). The selectivity for IGF-IR over IR is observed in the intact cell system, but not in the in vitro biochemical assays where the recombinant protein fragments corresponding to IGF-IR or IR are used, suggesting that conformation and selectivity may differ from the native enzymes in intact cells. IGF-IR/IR selectivity in cells, but not with in vitro enzymatic assays, has been previously reported (16). These data suggest that cellular assays may be preferred over biochemical assays to meaningfully assess selectivity of a novel pharmacologic agent between closely related target enzymes (39).

**Blockade of the Active IGF-II/IGF-IR Autocrine Loop by PQIP in a Human GEO Colorectal Cancer Cell Line**

To assess the effects of PQIP beyond the artificial 3T3/huIGF1R cell line, GEO human colorectal cancer cells were further evaluated for both basal phosphorylation of IGF-IR and expression of IGF-I and IGF-II (Fig. 2). Compared with the NCI-H292 non–small cell lung carcinoma cell line, the GEO cell line has significant and sustained basal phosphorylation of IGF-IR for at least 48 h under serum-free conditions without ligand stimulation (Fig. 2A). Accordingly, mRNA for IGF-II but not for IGF-I was detected in GEO cells, whereas little to no IGF-I or IGF-II mRNA was detected in NCI-H292 cells (Fig. 2B). In addition, conditioned medium derived from GEO cells stimulated tyrosine phosphorylation of IGF-IR in serum-starved NCI-H292 cells (Fig. 2C). The effect of conditioned medium on IGF-IR phosphorylation was diminished in a dose-dependent manner when the conditioned medium was preincubated with a neutralizing IGF-II antibody or nonspecific IgG at indicated concentrations. These data clearly suggest the presence of an active IGF-II/IGF-IR autocrine loop in GEO cells.

The ability of PQIP to block the IGF-II/IGF-IR autocrine loop in GEO cells was further evaluated through measurement of effects on downstream signaling pathways. PQIP blocks the active IGF-II autocrine loop in GEO cells as indicated by the complete inhibition of IGF-I–stimulated phosphorylation of IGF-IR well below the basal phosphorylation level. Furthermore, PQIP effectively inhibited AKT...
activation but not ERK1/2 activation in the presence of 10% FCS (Fig. 2E), suggesting that phosphorylated AKT is IGF-IR dependent and ERK1/2 can be activated by non-IGF-IR-dependent mechanisms in GEO cells (Fig. 2E). Accordingly, PQIP was found to effectively induce apoptosis in GEO cells in the presence of 10% FCS, as indicated by induction of poly(ADP)ribose polymerase cleavage (Fig. 2F; ref. 44) and induction of DNA fragmentation (data not shown). In cell-based functional assays, the antiproliferative potency of PQIP is comparable between 0.5% FCS and 10% FCS (Table 1), suggesting that autocrine IGF-II is the main driver for GEO cell proliferation even in the presence of serum. Furthermore, GEO cells show increased sensitivity to PQIP when grown in soft agar (Table 1), consistent with the role of IGF-IR in cell transformation (1–3). These data clearly show that PQIP effectively blocks the active IGF-II/IGF-IR autocrine loop essential for GEO cell growth and survival. Moreover, the effect of PQIP on inhibition of cell proliferation was directly compared with two neutralizing antibodies against IGF-IR, MAB391 and α-IR3, in an MCF-7 human breast cancer cell line (45). PQIP was found to have similar activity when compared with the antibodies (Supplementary Fig. S1). Taken together, these results, along with the kinase selectivity data, indicate that the biological effects of PQIP are a direct result of blockade of IGF signaling.

**Effect of PQIP on Tumor Cell Proliferation**

The effect of PQIP on tumor cell proliferation was determined among a panel of human tumor cell lines (Supplementary Table S2). A number of colorectal, breast, and pancreatic cancer cell lines responded, indicating that IGF-IR kinase inhibitors may show broad antitumor activity regardless of tumor type. All of these cell lines were found to express IGF-IR (not shown), although there was no direct correlation between IGF-IR expression level and sensitivity to PQIP. The reasons for insensitivity of some cell lines are unclear, but could relate to expression of ABC transporters (known for Panc1), activating mutations in downstream signaling components (e.g., phosphatidylinositol 3-kinase mutation in HCT116) or dependence on growth factor receptors other than IGF-IR.

It was noted that the IC50 (600 nmol/L) for inhibition of proliferation (Table 1) is higher than that (36 nmol/L) for inhibition of phosphorylated IGF-IR (Fig. 2E) in GEO cells. Although the possibility of an off-target activity of PQIP against kinase(s) not measured cannot be ruled out, one more likely explanation for the observed difference in the IC50 values may be that GEO cells can also respond to autocrine IGF-II with an IR-A–mediated proliferative response. IR-A, an insulin receptor splice variant lacking exon 11, is known to function as a high-affinity receptor for IGF-II and mediates predominantly proliferative effects compared with the principally metabolic effects elicited by insulin stimulation of the IR-B isoform that includes exon 11 (1). GEO cells were found to express mRNA for IR-A at a level ~10-fold less than IGF-IR as determined by reverse transcription-PCR (data not shown). Because IGF-II may also stimulate proliferation of GEO cells via IR-A, and PQIP...
is ~10-fold less potent in blocking the insulin receptor than IGF-IR, higher concentrations of PQIP may be necessary to effectively block both IGF-IR and IR-A mediated downstream signaling contributions to GEO cell proliferation.

**In vivo Efficacy of PQIP in Pharmacodynamic Models**

Pharmacokinetic analysis of PQIP in mice revealed that plasma levels of PQIP (C_max and AUC) increased approximately linearly between oral dose levels of 5 to 200 mg/kg, and ~100% oral bioavailability of PQIP was observed when comparing the AUC to that after i.v. administration at 10 mg/kg (data not shown). In addition, plasma samples were also analyzed by high-performance liquid chromatography with UV detection at 350 nm to investigate in vivo metabolism. No metabolites of >10% of PQIP in plasma were detected in any samples (data not shown), suggesting that no significant contribution to in vivo efficacy seems to arise from metabolites in this species. These pharmacokinetic properties warranted extensive characterization of the in vivo effect of PQIP in mice using oral administration.

To assess the drug exposure required for inhibition of tumor IGF-IR in vivo, a pharmacodynamic experiment was conducted first in 3T3/huIGF1R tumors in which the relationship of inhibition of IGF-IR phosphorylation (pharmacodynamic) and drug exposure (pharmacokinetic) was evaluated after a single oral dose of 75 mg/kg (Fig. 3A and B). Greater than 95% inhibition of tumor IGF-IR phosphorylation by PQIP was achieved by 4 h and was maintained for at least 24 h at plasma drug concentrations as low as 3.85 μmol/L (Fig. 3B). In the GEO xenograft model, a single oral dose of 25 mg/kg resulted in 57% inhibition of tumor IGF-IR phosphorylation by 4 h, whereas 80% inhibition was achieved at 16 h and was maintained for at least 24 h (data not shown). In comparison, 90% inhibition of GEO tumor IGF-IR phosphorylation could be maintained for at least a 24 h period when PQIP was dosed at 100 mg/kg (Fig. 3C and D). These observations, together with the greater TGI at 75 to 100 mg/kg compared with 25 mg/kg (Fig. 4A and B), suggest that maximal antitumor efficacy requires maintenance of plasma levels sufficient to chronically suppress 90% inhibition of IGF-IR phosphorylation in tumors.

The significant phosphorylated IGF-IR levels that were detected in the GEO xenograft (Fig. 3C), but not in HT29 and H526 xenografts (data not shown), which express abundant IGF-IR, indicates that murine plasma IGF may be insufficient to activate IGF-IR in xenograft models, and likely contributes little to the activation of IGF-IR phosphorylation in the GEO xenograft. Furthermore, the IGF-IR phosphorylation detected in GEO xenograft tumors indicates that the IGF autocrine loop detected in cell culture is also operative in vivo.

**In vivo Efficacy of PQIP in Tumor Xenograft Models**

To evaluate the in vivo efficacy of PQIP, TGI studies were undertaken in both 3T3/huIGF1R and GEO tumor xenograft models. All of these studies were done using 25 mmol/L tartaric acid as the vehicle with once daily oral dosing of the drug for 14 consecutive days. In all of the studies, minimal effects on body weight (<10% loss) were observed, although PQIP has been found to inhibit murine IGF-IR autophosphorylation with potency similar to that observed with human IGF-IR (Supplementary Fig. S2). In the 3T3/huIGF1R model, there was significant dose-dependent TGI at all doses tested between 25 and 100 mg/kg (Fig. 4A). Daily oral dosing of 25 or 50 mg/kg resulted in 70% to 74% mean TGI over the dosing period, whereas 75 or 100 mg/kg resulted in 86% and 98% mean TGI, respectively (Fig. 4A). Antitumor efficacy was also achieved in the human GEO xenograft model when PQIP was dosed orally for 14 consecutive days (Fig. 4B). However, in the GEO model, doses of 25 and 50 mg/kg gave equivalent antitumor effects with ~70% to 80% mean TGI observed over the dosing period. Increasing the dose

---

**Figure 4.** Antitumor activity and effect on blood glucose of orally dosed PQIP in mouse models. **A,** dose-dependent inhibition of 3T3/huIGF1R tumor xenograft growth by once daily oral dosing of PQIP for 14 d. **B,** dose-dependent inhibition of GEO tumor xenograft growth by once daily oral dosing of PQIP for 14 d, followed by outgrowth of tumors in the absence of dosing. **C,** effect on nonfasting blood glucose at indicated times in CD-1 mice after 3-d dosing of PQIP at 100 mg/kg. **D,** effect on glucose clearance in fasted CD-1 mice after 3-d dosing at 25, 75, or 125 mg/kg PQIP. Blood glucose was measured at indicated time points after the glucose challenge.
to 100 mg/kg resulted in a mean TGI of 97% associated with a significant growth delay (24 days) after cessation of drug treatment (Fig. 4B). These TGI data, taken together with the pharmacodynamic data, suggest that 80% target inhibition is sufficient for significant antitumor effects in the GEO colon carcinoma model, whereas increasing the amount of target inhibition over 24 h further improved the antitumor efficacy.

Preclinical observations that tumors with an IGF-II/IGF-IR autocrine loop are especially sensitive to IGF-IR inhibition suggest that tumor IGF-II overexpression and/or basal IGF-IR phosphorylation may be useful biomarkers to predict clinical efficacy. IGF-II is particularly important in the context of human cancers because it is expressed in the stromal components of cancers, is present in adult humans at high circulating levels, and does not exhibit the same magnitude of age-dependent decline as IGF-I levels. Moreover, the lack of these high circulating levels of IGF-II in rodents (1) limits IGF-II/IGF-IR paracrine stimulation in tumors when using mouse models. Therefore, mouse models may underestimate the importance of the IGF pathway in human cancers, suggesting that PQIP may also be efficacious in human cancers driven by an IGF-II paracrine signaling.

Effect of PQIP on Blood Glucose in Mice

Cellular selectivity data indicate that PQIP selectively inhibits human IGF-IR relative to human and mouse IR, although mouse IR seems to be more sensitive. These data suggest that a therapeutic window would exist in the mouse, and that in humans this therapeutic window would be greater with respect to hyperglycemia. To determine whether cellular IR selectivity is predictive of a therapeutic window to allow efficacy without substantial hyperglycemia in vivo, PQIP was tested in nonfasted mice. Following 3 consecutive daily oral doses of vehicle or 100 mg/kg of PQIP, <30% blood glucose elevation was observed in the PQIP-treated mice (Fig. 4C). To further evaluate the effects of PQIP on glucose clearance, a glucose tolerance test was conducted in mice treated with vehicle alone or with PQIP at 25, 75, or 125 mg/kg for 3 consecutive days. Before administration of the glucose load, there was no increase in fasting blood glucose in response to PQIP. Upon administration of the glucose load, there was an ~19% AUC increase in blood glucose in the 125 mg/kg–treated animals compared with the controls. At 2 h after glucose challenge, 15% glucose elevation in mice dosed with the highest dose (125 mg/kg) of PQIP compared with the control animals was observed (Fig. 4D). Although the effect of all dose levels of PQIP on glucose clearance was slight, there was a trend toward dose dependence with lower PQIP doses showing lesser effects. These data suggest that selective IGF-IR kinase inhibitors like PQIP may provide a therapeutic window in humans for maintaining an efficacious exposure without significantly affecting blood glucose.

In summary, PQIP represents a potent and selective small-molecule kinase inhibitor of IGF-IR. The cellular selectivity for human IGF-IR relative to the insulin receptor confers a therapeutic index to inhibit IGF-IR–driven tumor growth in vivo without causing significant hyperglycemia. Given that IGF-IR–mediated proliferative and survival signaling is required for some human malignancies, PQIP and related IGF-IR kinase inhibitors represent promising anticancer therapeutics, particularly for tumors that depend on IGF-II autocrine or paracrine signaling. In addition, activation of the IGF-IR protects tumor cells from apoptosis induced by a variety of anticancer agents (30, 46–48), and PQIP can potentiate the efficacy of other antitumor agents, such as erlotinib (49). Hence, this class of IGF-IR inhibitors should have broad clinical utility for treatment of cancers alone or in combination with other antitumor therapies.

Molecular Cancer Therapeutics 2167


Molecular Cancer Therapeutics

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling \textit{in vitro} and inhibits insulin-like growth factor-I receptor–dependent tumor growth \textit{in vivo}

Qun-sheng Ji, Mark J. Mulvihill, Maryland Rosenfeld-Franklin, et al.


Updated version

Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-07-0070

Supplementary Material

Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2007/09/24/1535-7163.MCT-07-0070.DC1

Cited articles

This article cites 48 articles, 22 of which you can access for free at:
http://mct.aacrjournals.org/content/6/8/2158.full.html#ref-list-1

Citing articles

This article has been cited by 29 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/6/8/2158.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.